Filing Flows › Ginkgo Bioworks Holdings (DNA) › Q4 2024
Ginkgo Bioworks Holdings (DNA) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Feb 25, 2025
Ginkgo Bioworks Holdings (DNA) reported revenue of $43.8M for the fourth quarter 2024 (Q4 2024), +26% from a year earlier and -51% from the quarter before. Operating margin was -236.3%, net loss $108M (245.2% of revenue).
Ginkgo Bioworks Holdings, Q4 2024: revenue $43.8M (+26% year over year), operating margin -236.3%, net loss $108M, operating cash flow −$42.4M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $43.8M | -51% | +26% |
| Operating profit | −$104M | — | — |
| Net earnings | −$108M | — | — |
| Operating cash flow | −$42.4M | — | — |
What changed
Revenue was $43.8M in Q4 2024, up 26% year over year and down 51% from the previous quarter. Cell Engineering was the largest line at 79% of revenue.
Operating costs exceeded revenue by $103.6M, an operating margin of -236.3%. Total costs fell 31% while revenue rose 26%. The fastest-growing cost line was Other operating costs (+108%). The quarter ended with a net loss of $107.5M, wider than the previous quarter's $56.4M loss.
Operating cash flow was −$42.4M. Non-cash charges added back $15.7M of depreciation and amortization and $20.6M of share-based compensation. Working capital and other items added $28.9M. Capital expenditures of $13.7M exceeded it, leaving free cash flow of −$56.1M.
Questions
What was Ginkgo Bioworks Holdings' revenue in the fourth quarter 2024?
Ginkgo Bioworks Holdings (DNA) reported revenue of $43.8M for the fourth quarter 2024 (Q4 2024), +26% from a year earlier and -51% from the quarter before.
Was Ginkgo Bioworks Holdings profitable in the fourth quarter 2024?
Operating loss was $104M (-236.3% of revenue) and net loss $108M.